Bempedoic acid/ezetimibe Alternatives Compared
| Bempedoic acid/ezetimibe | Repatha (evolocumab) | Atorvastatin |
|
|---|
| Bempedoic acid/ezetimibe | Repatha (evolocumab) | Atorvastatin |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
The combination of bempedoic acid and ezetimibe decreases LDL-C levels by more than either drug alone. It is usually given in combination with other cholesterol-lowering treatments. Bempedoic... View more |
Prescription only
Repatha is a PCSK9 inhibitor that may be used to reduce LDL-C levels in people with primary hyperlipidemia and HoFH, and also to reduce the risk of cardiovascular events in adults with established... View more |
Prescription only
Atorvastatin is effective at lowering cholesterol; however, its use may be limited by side effects such as muscle pain. Prescribed for High Cholesterol, High Cholesterol - Familial Homozygous, High... View more |
Related suggestions High Cholesterol
High Cholesterol, Familial Heterozygous
|
|||||||||||||||
| More about Bempedoic acid/ezetimibe | More about Repatha (evolocumab) | More about Atorvastatin | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Bempedoic acid/ezetimibe has an average rating of 9.4 out of 10 from a total of 16 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 0% reported a negative effect. |
Repatha has an average rating of 5.3 out of 10 from a total of 688 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 46% reported a negative effect. |
Atorvastatin has an average rating of 4.3 out of 10 from a total of 299 ratings on Drugs.com. 28% of reviewers reported a positive effect, while 54% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Repatha side effects |
View all Atorvastatin side effects |
|||||||||||||||||
| Drug Class | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
Lower cost generic |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Repatha prices |
View all Atorvastatin prices |
||||||||||||||||
| Dosage Forms | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Nexlizet |
N/A |
Atorvaliq, Lipitor | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
|
22 hours |
408 hours |
14 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 110 drugs are known to interact with Bempedoic acid/ezetimibe:
|
A total of 2 drugs are known to interact with Repatha:
|
A total of 402 drugs are known to interact with Atorvastatin:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|||||||||||||||||
| Disease Interactions | ||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
N/A |
August 27, 2015 |
December 17, 1996 |
||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient Resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
|
N/A |
||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.